By Sheri Kasprzak
Atlanta, March 17 - MIV Therapeutics Inc. said it plans to sell up to $1 million in convertible debentures in a private placement.
The debentures are due 180 days after the closing of the offering and are convertible into up to 4 million shares at $0.25 each.
The investors will also receive warrants for up to 2 million shares at $0.25 each for five years.
Casimir Capital LP is the placement agent.
The deal is expected to close April 30.
Based in Vancouver, B.C., MIV develops biocompatible coatings for use in cardiovascular stents.
| Issuer: | MIV Therapeutics Inc.
|
| Issue: | Convertible debentures
|
| Amount: | $1 million (maximum)
|
| Maturity: | 180 days
|
| Conversion price: | $0.25
|
| Conversion ratio: | Up to 4 million common shares
|
| Warrants: | Up to 2 million shares
|
| Warrant expiration: | Five years
|
| Warrant strike price: | $0.25
|
| Placement agent: | Casimir Capital LP
|
| Announcement date: | March 17
|
| Settlement date: | April 30
|
| Stock price: | $0.55 at close March 17
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
